Skip to content
Comparison

Epithalon vs NAD+

Epithalon and NAD+ are commonly compared for longevity signaling versus metabolic coenzyme replenishment. Epithalon is usually favored for aging-pathway targeting and cycle-based protocols, while NAD+ is often preferred for energy metabolism and mitochondrial support orientation. This head-to-head analysis focuses on mechanism, trial outcomes, dosing context, evidence quality, regulatory status, and practical decision points for safer YMYL decision-making.

4.3(112 ratings)

Quick Answer

For longevity signaling versus metabolic coenzyme replenishment, the better choice depends on your primary endpoint. Epithalon is stronger when the priority is longevity-experiment protocols. NAD+ is stronger when the priority is fatigue and metabolic resilience support. Use evidence grade, dose intensity, access constraints, and tolerability profile to match therapy to the patient profile rather than choosing by hype alone.

Head-to-Head Comparison

CriteriaEpithalonNAD+
Primary mechanismSynthetic tetrapeptide investigated for pineal and telomerase-related aging pathwaysCoenzyme replenishment strategy for mitochondrial and metabolic pathways
Strongest clinical signalLongevity and immune-aging signals in preliminary human and animal studiesSignals for improved cellular energetics and metabolic resilience
Typical dosing contextCommon protocols use short cycles (e.g., 5-10 mg daily for 10-20 days)IV, IM, SC, or oral precursor protocols vary widely
AdministrationSubcutaneous or intramuscular injectionClinic infusions/injections or oral support stacks
Evidence quality gradePreliminary; significant need for modern large RCTsModerate mechanistic evidence; heterogeneous clinical outcomes
Regulatory statusNot FDA-approvedNot an FDA-approved disease-specific peptide therapy
Side-effect burdenGenerally tolerated in reported use, but data depth is limitedGenerally tolerated; protocol quality and formulation matter
Cost/access contextModerate cycle-based peptide costHigh for infusion-heavy protocols
Best candidate profileUsers targeting longevity-oriented experimental protocolsEnergy/fatigue and metabolic-support strategies
Main limitationEvidence maturity below mainstream geroscience interventionsOutcome heterogeneity and protocol standardization gaps
Best use case in this comparisonlongevity-experiment protocolsfatigue and metabolic resilience support

When to Choose Each

Choose Epithalon

Best for longevity-experiment protocols.

Choose NAD+

Best for fatigue and metabolic resilience support.

Verdict

If the main goal is longevity-experiment protocols, Epithalon is usually the better first-line choice. If the main goal is fatigue and metabolic resilience support, NAD+ is typically the better fit. Reassess outcomes at 8-16 weeks with objective metrics, then adjust only when response, safety, or adherence data justify it. In high-risk populations, physician-guided personalization matters more than any generic ranking.

References

  1. Peptide promotes overcoming of the division limit in human somatic cells (2003) — PubMed
  2. Effect of Epithalon on the age-related changes in the pineal gland and melatonin level in old macaques (2003) — PubMed
  3. Peptide regulation of gene expression and protein synthesis in bronchial epithelium (2005) — PubMed
  4. The neuroendocrine theory of aging and degenerative disease: toward a unified model of aging (2002) — PubMed

Compare Telehealth Providers

Find the right provider for your peptide therapy needs

Hims & Hers

Most Popular
4.3

Starting at $199/mo

Hims & Hers is a leading telehealth platform offering physician-supervised GLP-1 weight loss programs including compounded semaglutide and tirzepatide. Board-certified providers, async or video consults, and medication shipped to your door.

✓Large, established platform with strong physician network
✓Compounded semaglutide available where branded shortages exist
✓Easy async consult — no video call required
✗Does not offer a wide range of peptides beyond GLP-1s
✗Pricing is on the higher end for GLP-1 programs

Henry Meds

Most Peptides
4.2

Starting at $249/mo

Henry Meds is a telehealth provider specializing in hormone optimization and peptide therapy. Beyond GLP-1 weight loss, Henry Meds offers testosterone replacement therapy, growth hormone peptides, and other advanced hormonal protocols managed by licensed physicians.

✓Broadest peptide therapy menu of any major telehealth provider
✓Growth hormone peptides (sermorelin, ipamorelin, CJC-1295) available
✓Repair peptides including BPC-157 and TB-500
✗Higher starting price due to comprehensive programs
✗More complex onboarding including lab work requirements

Ro Body

Best Value
4.1

Starting at $149/mo

Ro Body is a telehealth weight management program powered by GLP-1 medications. Ro connects patients with licensed providers who prescribe compounded semaglutide or branded GLP-1 therapies depending on eligibility, paired with behavioral coaching.

✓Competitive pricing starting at $149/mo
✓Dedicated health coach included in program
✓Strong clinical protocols with lab-work integration
✗Narrower peptide offering — GLP-1s only
✗Video consult required for initial visit

Calibrate

4.0

Starting at $199/mo

Calibrate is a metabolic health company offering a one-year GLP-1 program built around four pillars: food, sleep, exercise, and emotional health. Calibrate works with insurance to cover medication costs and provides extensive behavioral coaching alongside prescriptions.

✓Insurance navigation support for medication coverage
✓Evidence-based one-year program with structured milestones
✓Four-pillar lifestyle coaching (food, sleep, exercise, emotional health)
✗Annual program commitment required
✗Primarily focused on GLP-1s — no broader peptide therapy

Found

3.9

Starting at $129/mo

Found is a weight management telehealth platform that combines GLP-1 medications with behavioral coaching and a supportive community. Found emphasizes a whole-person approach, pairing pharmacological treatment with lifestyle intervention for sustainable results.

✓One of the more affordable monthly program fees
✓Strong community and peer support features
✓Certified health coaches with regular check-ins
✗Medication billed separately from program fee — total cost can be higher
✗Limited peptide variety beyond standard GLP-1s

Sponsored · We may earn a commission. Learn more · Updated February 2026

Frequently Asked Questions

Which has stronger evidence for longevity signaling versus metabolic coenzyme replenishment — Epithalon or NAD+?
Epithalon is graded as preliminary; significant need for modern large rcts evidence in this context, while NAD+ is graded as moderate mechanistic evidence; heterogeneous clinical outcomes. In practice, strength depends on whether you prioritize longevity-experiment protocols or fatigue and metabolic resilience support. Favor the option with endpoint data closest to your primary goal, and avoid extrapolating beyond studied populations.
Can Epithalon and NAD+ be combined or sequenced?
Sometimes, but only with clinician oversight. A common framework is to start with one agent, track objective response for 8-16 weeks, then switch or sequence if outcomes plateau or tolerability is poor. Combination protocols may increase both cost and adverse-effect complexity, so they should be justified by clear endpoint-based rationale.
What should be monitored before and during treatment?
Baseline assessment should include diagnosis confirmation, comorbidity risk, and contraindications. During therapy, monitor target outcomes (symptoms, body composition, labs), adverse effects, and adherence burden. For endocrine/metabolic strategies, periodic glucose, lipids, organ function, and indication-specific labs help keep risk proportional to expected benefit.

Explore next